Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8653092 | PHARMING | Tetrahydro-pyrido-pyrimidine derivatives |
Feb, 2032
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Mar 24, 2030 |
New Chemical Entity Exclusivity (NCE) | Mar 24, 2028 |
Drugs and Companies using LENIOLISIB PHOSPHATE ingredient
NCE-1 date: 2027-03-25
Market Authorisation Date: 24 March, 2023
Treatment: NA
Dosage: TABLET;ORAL